Biomedical Engineering Reference
In-Depth Information
skin products have suffered setbacks in recent years and have gar-
nered a considerably lower market share than commercial promot-
ers anticipated. The reasons may be that the mechanism of action
of these products is not universally agreed upon, that is, graft “take”
is not usually considered to occur, and that these products do not
specifically match a clinical treatment to an underlying pathology.
18
CurrentlyavailableproductsapprovedbytheFoodandDrugAdmin-
istration as matrices for wound repair include Epicel
R
(Genzyme
Tissue Repair), Integra
R
(Integra Life Sciences), Alloderm
R
(Life
Cell), Transcyte
R
(Advanced Biohealing), Apligraf
R
(Organogene-
sis),Orcel
R
(Ortecinternational),andsoon.Table39.1showsexam-
ples of commercially created skin substitutes.
Table 39.1. Classification of commercialized skin substitutes.
Main component &
Description
Characterization
commercial product
name (Manufacturer)
Epidermal substitutes
Epicel
R
(GenzymeTissue
Repair Corporation)
Culturedepidermal
autograftgrown from
patient skin biopsy on
petrolatum gauzebacking
Deep dermalor full-thickness
burns over a total-body
surfacearea
>
=30%coverage
with littlerisk of rejection. 3
wk required to producefragile
confluent sheets.
(Fidia Advanced
Biopolmers)
Laserskin
R
Subconfluent, autologous
keratinocytes from skin
biopsy in aperforatedHA
matrix
A less fragile deliverysystem
for keratinocytes, 100%
esterified HA membrane/cell
interaction properties
improve mechanicalstability.
Minimum of 3 wk required to
expand keratinocyte
population.
EpiDex
R
Cultured, autologous
outer root sheath hair
follicle cellson silicon
membrane
Using substituteto takeup to
6 wk after harvesting, cells
haveincreased proliferative
capacity and can be
cryopreservedfor repeat
applications. Successin
chronic ulcer treatment.
Product fragile.
(Modex
Therapeutiques)
(
Contd.
)
Search WWH ::
Custom Search